(Alliance News) - Roquefort Therapeutics PLC on Thursday said it has proposed the sale of subsidiary Lyramid Pty Ltd to Pleiades Pharma Ltd for a minimum of USD10 million. Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - Roquefort Therapeutics PLC on Monday announced its patent for mesodermal killer, or MK, cell therapy has been approved by the Japan Patent Office. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
Roquefort Therapeutics PLC - London-based biotechnology company - Says it has opted against a fundraise following "unusual share price movements". The company had engaged advisers to commence "market soundings" in relation to a potential placing, but says that "incorrect bulletin board comments regarding a speculative placing price," which in turn impacted its share price, turned it against the idea. Shares in Roquefort dropped 36% on Thursday from 6.89 pence each to 4.41 pence, having hovered around the 7p mark for the whole of March. Read More
(Alliance News) - Roquefort Therapeutics PLC on Monday reported progress in cancer research under two of its medicine development programmes. Read More
Roquefort Therapeutics PLC - London-based biotechnology company, focused on developing medicines for hard-to-treat cancers - Says it has continued studies on its MK cells in validated models of natural killer (NK) cell activation and cytotoxicity, showing an anti-cancer effect in leukaemia with superior efficacy to NK cells alone. Confirms that MK cells activate NK cells. Read More
(Alliance News) - Roquefort Therapeutics PLC on Monday said its Mesodermal Killer cell programme has reached a "significant" milestone. Read More
(Alliance News) - The following is a round-up of earnings of London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Roquefort Therapeutics PLC on Monday said it has filed an international phase PCT patent for its anti-cancer mRNA and RNA oligonucleotide therapies. Read More
Roquefort Therapeutics PLC - London-based biotechnology company, focused on developing medicines for hard-to-treat cancers - Announces the development of new small interfering ribonucleic acid sequences. Says sequences expand its portfolio of siRNA medicines, which it purchased through its acquisition of London-based cancer medications company Oncogeni Ltd in September. Adds it has completed a new patent filing to strengthen its siRNA patent pisition. Says the sequences are being developed alongside nano-particle delivery systems to target hard-to-treat, high mortality solid cancers. Results are expected in the fourth quarter of 2023. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Roquefort Therapeutics PLC on Monday said its recent in vivo study targeting midkine-expressing cancers has shown "significant" success by its lead antibody programmes, which its CEO said "demonstrate the potential for a best-in-class medicine." Read More
Roquefort Therapeutics PLC - London-based biotech company focused on developing medicines for hard-to-treat cancers - Says recently completed in vitro studies for new messenger ribonucleic acid therapeutic show "statistically significant reduction" in proliferation and migration of breast and liver cancer. Study was part of Roquefort's new anti-cancer mRNA therapeutics platform focused on the Midkine growth target. The MDK mRNA programme was tested in validated in vitro cancer models to evaluate effect on growth and migration. Roquefort acknowledges that these are early results but says therapeutic shows potential to become first-in-class cancer treatment if they are replicated in clinical trials. It recently updated its filed patents to protect MDK mRNA programme compositions and methods. Programme now will move to in vivo studies. Read More
Roquefort Therapeutics PLC - London-based biotech company focused on developing medicines for hard-to-treat cancers - Share suspension lifted, following the publication of its results Monday. Read More
(Alliance News) - Roquefort Therapeutics PLC reported an increased loss for 2022 as costs rose in several areas, with the year including a successful acquisition, and said it expects to meet its targets for the current year. Read More